REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression (REGOVAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02584465

Recruitment Status : Completed

First Posted : October 22, 2015

Last Update Posted : September 6, 2023

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

Bayer

Information provided by (Responsible Party):

ARCAGY/ GINECO GROUP

Study Details
Tabular View
No Results Posted
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	September 19, 2021
Actual Study Completion Date :	September 19, 2021

To Top